Clinical Trial Update: Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial [Phase 2, Phase 3]

View source ↗

Summary

A randomized controlled trial evaluating N-acetylcysteine to prevent anti-tuberculosis drug-induced liver injury in tuberculosis patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Drug-induced Liver Injury
• Tuberculosis

Drugs mentioned

• N-acetylcysteine (N-acetylcysteine)

Snippet

Sponsor: Mahidol University | Conditions: Tuberculosis, Drug Induced Liver Injury | Phase 2, Phase 3 | Status: UNKNOWN